Modality
Gene Therapy
MOA
GLP-1ag
Target
FcRn
Pathway
NF-κB
HS
Development Pipeline
Preclinical
~Nov 2019
→ ~Feb 2021
Phase 1
~May 2021
→ ~Aug 2022
Phase 2
Nov 2022
→ Nov 2030
Phase 2Current
NCT08437630
116 pts·HS
2022-11→2028-05·Terminated
NCT04020869
2,674 pts·HS
2024-10→2030-11·Terminated
2,790 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-05-232.1y awayPh3 Readout· HS
2030-11-234.6y awayPh3 Readout· HS
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Termina…
P2/3
Termina…
Catalysts
Ph3 Readout
2028-05-23 · 2.1y away
HS
Ph3 Readout
2030-11-23 · 4.6y away
HS
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08437630 | Phase 2/3 | HS | Terminated | 116 | FEV1 |
| NCT04020869 | Phase 2/3 | HS | Terminated | 2674 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| ITC-879 | Intra-Cellular | Approved | FcRn | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn |